STTK · Shattuck Labs, Inc.

The thesis

Shattuck Labs has no patient efficacy data for its lead drug SL-325 until the first half of 2028, so the shares trade on the story and on two near dated events: the October 2026 investigational new drug (IND) filing and the third-quarter report. The shares closed at $5.77 on 27 October 2026, 28.4% under the 52-week high of $8.06, with a 3-month decline of 19.7% and a 14-day Relative Strength Index (RSI) of 52.1.

SL-325 blocks death receptor 3 (DR3), the receptor for the inflammatory protein TL1A. The 8 June 2026 Phase 1 release reported complete receptor occupancy at doses of 0.1 mg/kg and above in 72 healthy volunteers. No Crohn's disease, ulcerative colitis or hidradenitis suppurativa (HS) patient has yet appeared in a reported efficacy dataset.

On 1 October 2026 Shattuck announced the Phase 2 trial RECEPTIVE-HS1 in moderate-to-severe HS: about 150 patients, two SL-325 dose levels against placebo, and HiSCR50 response at Week 16 as the primary endpoint. The company guides an IND submission in October 2026 and data in the first half of 2028 (RTTNews, 1 October 2026). A search on 28 October 2026 found no release confirming the submission.

Analysts keep adding coverage. UBS initiated at Buy with a $17 target on 12 October 2026 (Benzinga), and Evercore initiated at Buy on 21 October 2026 (Benzinga). The consensus target of 11 analysts polled by S&P Global was $14.67 on 1 October 2026, more than double the last close.

The narrative is maturing: the pipeline story is well known and three initiations since 24 August 2026 have not returned the shares to the $6.84 close of 1 October 2026. The $5.75 weekly-close level in the previous note sits just under the 27 October 2026 close, so the shares are back at that level without having cleared it by a margin.

Bullish and bearish views on Shattuck Labs, Inc.

The bull case on Shattuck Labs, Inc. (STTK), in brief: Human target engagement is measured. The bear case: No patient data exists.

Bull case

• Human target engagement is measured. The 8 June 2026 release reported complete DR3 occupancy at 0.1 mg/kg and above in 72 healthy volunteers. That shows the drug reaches its target in people.
• Two Phase 2 indications exist. The 1 October 2026 release adds HS to the Crohn's disease programme, with about 150 patients in the HS trial. A positive result in either gives the mechanism a place to show itself.
• Cash covers the stated plan. Shattuck reported $208.3 million in cash, cash equivalents and short-term investments at 30 June 2026 and guided to fund operations into 2029 (Q2 2026 release, 11 August 2026). The guidance excludes further capital raises.
• Sell-side coverage keeps widening. Raymond James initiated at Strong Buy with an $18 target on 24 August 2026, UBS at Buy with $17 on 12 October 2026 and Evercore at Buy on 21 October 2026 (Benzinga). Needham's target is $19 and Wedbush's is $14 (Benzinga, 2 October 2026).

Bear case

• No patient data exists. The Phase 1 trial enrolled healthy volunteers only and reported anti-drug antibodies in 3.7% of treated participants (8 June 2026). Receptor occupancy does not measure remission or HiSCR50 response.
• Both readouts sit in 2028. Management guides Phase 2 data in Crohn's disease and HS to the first half of 2028. The only earlier dataset is SL-846 Phase 1, guided to 2027.
• Spending is rising. R&D expense was $11.7 million in Q2 2026 versus $8.7 million in Q2 2025, and the Q2 loss of $0.12 per share missed the $0.10 consensus estimate (Benzinga, 11 August 2026). A second Phase 2 trial adds cost.
• The shares have not followed the targets. The 3-month decline is 19.7% as of 27 October 2026 while four brokerages have initiated or raised targets since 24 August 2026. HC Wainwright lowered its target to $14 on 11 August 2026.

Price setup

The last close was $5.77 on 27 October 2026, up from $5.33 on 14 October 2026 (adjusted daily closes). The 52-week high is $8.06, 28.4% above the last close. The 14-day RSI of 52.1 is neutral, up from 35.5 on 14 October 2026.

The shares sit at the $5.75 weekly-close level named in the previous note. A daily close below $5.00 is the invalidation level for this note, 13.3% under the last close.

Crowding evidence is limited. Analyst coverage is heavy for a company without patient data, but no SEC Form 4 insider sales or new registration statements appear in filings for the past 30 days. The next earnings date is about two weeks away. The Q3 report will show any at-the-market share sales.

Catalysts, next 30 days

• ~10 November 2026, est.: Q3 2026 financial results. The date is inferred from the 11 August 2026 Q2 report and is unconfirmed. The report shows cash against $208.3 million at 30 June 2026, R&D spending, share count and whether the runway guidance into 2029 holds.
• ~2027, est.: SL-846 Phase 1 data, the next dataset of any kind.

Elapsed catalysts

• 31 October 2026, guided: IND submission for RECEPTIVE-HS1. The company guided October 2026 on 1 October 2026; no confirmation had been published by 28 October 2026. (passed 6d ago)

What would change the view

The case breaks if either SL-325 Phase 2 programme is put on hold, delayed or fails, or if the IND for RECEPTIVE-HS1 slips past October without explanation. A Q3 report that cuts the runway guidance below 2029, or a discounted equity offering, would also weaken it. A negative TL1A-class result from Merck (tulisokibart) or Roche (afimkibart) in inflammatory bowel disease would lower the value assigned to the mechanism.

On price, a daily close below $5.00 ends the case. A confirmed IND and a weekly close clearly above $5.75 would strengthen the near-term read but would not add patient data.

What it trades with

STTK trades with small and mid-cap biotechnology shares and with the TL1A mechanism. Clinical news from Merck's tulisokibart and Roche's afimkibart programmes in inflammatory bowel disease is the most direct outside influence. Share moves before 2028 depend on financing, filings and analyst actions, since no patient efficacy data is due.